anti-alpha-synuclein antibody

Anti-alpha-synuclein antibodies are a class of target-specific monoclonal antibody therapeutics designed to bind to alpha-synuclein (α-syn), a presynaptic neuronal protein that misfolds and aggregates into toxic fibrils (forming Lewy bodies) in synucleinopathies. These antibodies aim to inhibit the cell-to-cell propagation of pathological alpha-synuclein, reduce neurotoxicity, and promote clearance of aggregates. Prominent clinical-stage candidates in this class include prasinezumab (developed by Prothena and Roche) and amlenetug (Lu AF82422, developed by Lundbeck), which are being evaluated for disease-modifying effects in neurodegenerative disorders such as Parkinson's disease and multiple system atrophy (MSA).

Other names

anti-alpha-synuclein mAbanti-alpha-synuclein monoclonal antibodyanti-aSyn antibodyanti-aSyn mAbanti-α-synuclein antibodyanti-α-synuclein monoclonal antibody